This section contains information about Galapagos NV’s business for stockholders, potential investors, financial analysts and media.
Do you want to receive our press releases?
London, UK, and Mechelen, Belgium, April 29, 2003 – Inpharmatica Ltd a leading informatics-driven drug discovery company, and Galapagos Genomics NV, the Belgian functional genomics…
Mechelen, Belgium and Freising, Germany, April 7, 2003. Galapagos Genomics NV, the Belgian functional genomics company, and Degussa BioActives announced today that they have entered…
Mechelen, Belgium, January 16, 2003 — Galapagos Genomics, the Belgian functional genomics company, today announced that it has launched its SilenceSelect(TM) gene silencing platform. With…
Mechelen, Belgium, June 20, 2002 — Galapagos Genomics, the Belgian/Dutch functional genomics company, announced today that it has been awarded technology development grants in Belgium…
Mechelen, Belgium — May 21, 2002 – Galapagos Genomics NV announced today that Robin Brown has been appointed Chief Scientific Officer (CSO). Dr. Brown will…
Mechelen, Belgium, March 5, 2002 — Galapagos Genomics, the Belgian/Dutch functional genomics company, today announced the completion of a Euro21.4 million private placement. This first…
Mechelen, Belgium, January 23, 2002 — Galapagos Genomics NV, the Belgian functional genomics company, today announced that it has been awarded US Patent No. 6,340,595…
Mechelen, Belgium, January 23, 2002 — Galapagos Genomics NV, the Belgian functional genomics company, today announced a research collaboration with Exelixis, Inc., for the use…
Under the terms of the agreement, Galapagos will supply Euroscreen with an arrayed collection of secreted proteins and peptides (“peptide library”) from human cells infected…